Approval commences 1 November 2026 - DACARBAZIN LIPOMED dacarbazine 200 mg powder for solution for injection or infusion single-use vial (Germany)
Section 19A approved medicine
Approval commences 1 November 2026 - DACARBAZIN LIPOMED dacarbazine 200 mg powder for solution for injection or infusion single-use vial (Germany)
Section 19A approval holder
ORSPEC Pharma Pty Ltd ABN 15 634 980 417
Phone
02 4339 4239
Approved until
Status
Current
Medicines in short supply/unavailable
DBL DACARBAZINE 200mg powder for injection vial - ARTG 39954
Indication(s)
- Chemotherapy of metastatic malignant melanoma
- Chemotherapy of advanced soft tissue sarcomas (excluding mesotheliomas and Kaposi sarcomas) in adults.
Additional information
**Please note: start date of this approval is 1 November 2026**
Images
